BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24368535)

  • 1. Remarkable response to radioiodine therapy in a case of metastatic macrofollicular variant of papillary thyroid carcinoma.
    Marques P; Leite V; Bugalho MJ
    Clin Nucl Med; 2014 Feb; 39(2):219-21. PubMed ID: 24368535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm?
    Rosario PW
    Eur J Surg Oncol; 2017 Sep; 43(9):1802-1803. PubMed ID: 28743373
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.
    Scott E; Learoyd D; Clifton-Bligh RJ
    Future Oncol; 2016 Nov; 12(22):2603-2613. PubMed ID: 27387641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metachronous solitary metastasis of papillary thyroid cancer in the cavernous sinus: case report and review of literature.
    Chandarana MN; Epari S; Chaukar D; Moiyadi AV
    J Cancer Res Ther; 2012; 8(3):436-8. PubMed ID: 23174730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Axillary metastasis of papillary thyroid carcinoma: report of a case].
    El Khiati R; Ouaissi L; Rouadi S; Abada R; Mahtar M; Roubal M; Janah A; Essaadi M; Kadiri F
    Pan Afr Med J; 2013; 16():12. PubMed ID: 24498461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two patients with highly aggressive macrofollicular variant of papillary thyroid carcinoma.
    Cardenas MG; Kini S; Wisgerhof M
    Thyroid; 2009 Apr; 19(4):413-6. PubMed ID: 19355832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
    Wu X; Gu H; Gao Y; Li B; Fan R
    Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
    Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
    Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrofollicular variant of papillary thyroid carcinoma.
    Nakamura T; Moriyama S; Nariya S; Sano K; Shirota H; Kato R
    Pathol Int; 1998 Jun; 48(6):467-70. PubMed ID: 9702860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should radioactive iodine therapy be administrated in patient of papillary thyroid carcinoma?
    Zhao J; Dong J; Sun Q; Wang H; Zhang Z; Zhou X; Liao L
    Chin Med J (Engl); 2014; 127(16):3039-40. PubMed ID: 25131255
    [No Abstract]   [Full Text] [Related]  

  • 12. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual vignette.
    Saberi S; Esfandiari NH
    Endocr Pract; 2015 May; 21(5):558. PubMed ID: 25297672
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary Squamous Cell Carcinoma of Trachea Arising 4 Years After Radioiodine Treatment of Papillary Carcinoma of Thyroid.
    Tan TH; Lee BN
    Clin Nucl Med; 2016 May; 41(5):e259-60. PubMed ID: 26828143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
    Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Campennì A; Pignata SA; Baldari S
    Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy.
    Lang BH; Shek TW; Wan KY
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):236-242. PubMed ID: 27467318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare.
    Marti JL; Davies L; Haymart MR; Roman BR; Tuttle RM; Morris LG
    Thyroid; 2015 Jul; 25(7):865-6. PubMed ID: 25963001
    [No Abstract]   [Full Text] [Related]  

  • 19. [Value of (18)F-FDG dual head coincidence imaging in predicting the efficacy of radioiodine therapy for papillary thyroid carcinoma with cervical lymph node metastasis].
    Sun YG; Feng HJ; Liu JH; Hu R; Ouyang W
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1571-4. PubMed ID: 21945769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].
    Mäenpää H
    Duodecim; 2014; 130(6):573-9. PubMed ID: 24724456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.